Microsoft (MSFT) Stock Dips 4% Despite Majorana 2 Quantum Chip Announcement
Microsoft (MSFT) stock dropped 4.17% after unveiling Majorana 2 quantum chip. Analysis of the investment opportunity amid quantum...
Palantir (PLTR) Stock Under Scrutiny as UK Lawmakers Demand NHS Contract Exit
UK MPs demand exit from Palantir's (PLTR) £330M NHS contract, branding it a national security risk. Committee urges break clause a...
Nvidia (NVDA) Stock: Analyzing the New Microsoft Build AI Partnership Impact
Nvidia (NVDA) partners with Microsoft on unified AI stack. New RTX Spark PCs, GB300 systems, Azure integration, and Vera Rubin pla...
European Markets Decline as Middle East Tensions Drive Oil Rally
European markets dipped as Iranian strikes drove oil up 2%, hitting airlines. ECB rate hike expectations rose while Inditex surged...
Crude Oil Surges Toward $97 Amid Escalating US-Iran Conflict and Supply Concerns
Oil prices surge toward $97 as US-Iran tensions escalate near Strait of Hormuz, nuclear talks collapse, and US crude inventories d...
SpaceX Eyes Historic $1.75 Trillion Valuation in Upcoming IPO
SpaceX targets $1.75T valuation with $75B IPO at $135/share. Roadshow begins Thursday. Musk allocates 30% to retail investors. Ful...
DeepSeek Pursues $7.4 Billion in Debut Funding Round Led by Tencent and CATL
DeepSeek pursues $7.4B in its inaugural funding round, potentially reaching a $59B valuation with backing from Tencent, CATL, and...
Alphabet (GOOGL) Stock Drops 3.86% After UK Mandates AI Search Publisher Control...
Alphabet (GOOGL) stock dropped 3.86% after UK regulators imposed rules requiring Google to allow publishers to opt out of AI searc...
Meta (META) Stock Falls After EU Court Confirms Messenger Must Comply with Gatek...
Meta (META) stock falls 0.47% after EU's General Court upholds gatekeeper label for Messenger under DMA while annulling Marketplac...
Johnson & Johnson (JNJ) Stock Rises on Positive Nipocalimab Lupus Trial Data
Johnson & Johnson (JNJ) stock gains as nipocalimab demonstrates sustained lupus control in Phase 2 JASMINE trial, with strong auto...